Asia
PanGen Biotech Wins KRW2.8 Billion Service Contract; Shares Decline 5%
PanGen Biotech (KOSDAQ:222110) secured a research service contract to advance a production system and evaluate a non-clinical sample production system for an antibody treatment targeting Severe Fever with Thrombocytopenia Syndrome (SFTS).The contract, valued at 2.8 billion won, is valid till Dec. 31, 2028, according to a Monday filing by the biotechnology company with the Korea Exchange.Shares of Pangen Biotech fell more than 5% in recent trade.
KOSDAQ:222110
